Effect of ICRF 159 on immune responses.
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000187:drug effects; D006462:Hemolytic Plaque Technique; D007109:Immunity / Q000187:drug effects*; D007111:Immunity, Cellular / Q000187:drug effects; D007114:Immunization; D007659:Ketones / Q000008:administration & dosage / Q000494:pharmacology; D051379:Mice; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D012710:Serum Albumin, Bovine; D016038:Skin Transplantation; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D007659:Ketones; D010879:Piperazines; D012710:Serum Albumin, Bovine